Encompass Health (NYSE:EHC) Given New $100.00 Price Target at UBS Group

Encompass Health (NYSE:EHC) had its price target increased by UBS Group from $96.00 to $100.00 in a report released on Thursday, Marketbeat Ratings reports. They currently have a buy rating on the stock.

Several other analysts also recently commented on EHC. Barclays reduced their target price on Encompass Health from $113.00 to $109.00 and set an overweight rating for the company in a research note on Tuesday. SVB Leerink started coverage on Encompass Health in a report on Wednesday, July 10th. They set an outperform rating and a $100.00 price objective for the company. Truist Financial increased their target price on Encompass Health from $95.00 to $100.00 and gave the stock a buy rating in a report on Monday, July 15th. Mizuho upped their price objective on shares of Encompass Health from $93.00 to $95.00 and gave the stock a buy rating in a report on Thursday, April 25th. Finally, Royal Bank of Canada lifted their price objective on shares of Encompass Health from $83.00 to $95.00 and gave the company an outperform rating in a report on Wednesday, May 22nd. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $99.88.

Encompass Health Trading Down 1.6 %

EHC stock traded down $1.37 during mid-day trading on Thursday, reaching $85.72. The company’s stock had a trading volume of 759,309 shares, compared to its average volume of 659,747. Encompass Health has a 12 month low of $57.55 and a 12 month high of $94.38. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14. The business’s 50 day moving average price is $86.48 and its 200 day moving average price is $81.51. The company has a market cap of $8.63 billion, a price-to-earnings ratio of 23.17, a price-to-earnings-growth ratio of 1.45 and a beta of 0.89.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.10. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.30 billion. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. Encompass Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.95 EPS. On average, equities research analysts predict that Encompass Health will post 4.09 EPS for the current year.

Encompass Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, October 1st will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Tuesday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.15. Encompass Health’s payout ratio is presently 18.38%.

Insider Activity

In other Encompass Health news, insider Elissa Joy Charbonneau sold 10,000 shares of the business’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $85.02, for a total value of $850,200.00. Following the transaction, the insider now owns 18,594 shares of the company’s stock, valued at $1,580,861.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EHC. Commonwealth Equity Services LLC raised its holdings in shares of Encompass Health by 1.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 9,845 shares of the company’s stock worth $845,000 after purchasing an additional 123 shares during the period. Legacy Wealth Asset Management LLC lifted its position in shares of Encompass Health by 1.5% during the 1st quarter. Legacy Wealth Asset Management LLC now owns 8,619 shares of the company’s stock valued at $712,000 after buying an additional 130 shares during the last quarter. Smith Group Asset Management LLC grew its stake in shares of Encompass Health by 1.2% during the 1st quarter. Smith Group Asset Management LLC now owns 12,070 shares of the company’s stock worth $997,000 after acquiring an additional 140 shares during the period. Benjamin Edwards Inc. raised its stake in Encompass Health by 3.8% in the 4th quarter. Benjamin Edwards Inc. now owns 3,885 shares of the company’s stock valued at $259,000 after acquiring an additional 142 shares during the period. Finally, Horrell Capital Management Inc. lifted its holdings in Encompass Health by 0.5% during the first quarter. Horrell Capital Management Inc. now owns 29,371 shares of the company’s stock valued at $2,425,000 after purchasing an additional 147 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.